Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs

Rheumatology

Volumn 47, Issue 6, 2008, Pages 872-876

  Cantini, F ^a   Niccoli, L ^a   Nannini, C ^a   Cassara E ^a   Pasquetti, P ^a   Olivieri, I ^b   Salvarani, C ^c  

^a HOSPITAL OF PRATO   (Italy)

^b Madonna delle Grazie Hospital of Matera   (Italy)

^c Division of Rheumatology   (Italy)

Author keywords

Anti TNF drugs; Clinical remission; DMARDs; MTX; PsA; RA; Remission criteria

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL ARTHRITIS; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FREQUENCY ANALYSIS; HUMAN; HYPERTRICHOSIS; HYPOTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH SPASM; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44849131003     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken059     Document Type: Article

References (39)

1. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994;33:834-9.
3. McNugh NJ, Balachristian C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: A 5-year prospective study. Rheumatology 2003;42:778-83.
4. Khan M, Schentag C, Gladman DD. Clinical and radiological changes during psoriatic arthritis disease progression. J Rheumatol 2003;30:1022-6.
5. Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis: A clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979;9:75-97.
6. Gladman DD, Schuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA): An analysis of 220 patients. Q J Med 1987;62:127-41.
7. Kane D, Stafford L, Bresnihan B, Fitzgerald O. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology 2003;42:1460-8.
8. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: Multivariate risk model. J Rheumatol 1995;22:675-9.
9. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68-70.
10. Gladman DD, Farewell VT, Kopciuk K, Cook RJ. HLA antigens and progression in psoriatic arthritis. J Rheumatol 1998;25:730-3.
11. Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: A comparison with younger onset disease. Ann Rheum Dis 1999;58:226-9.
12. Balding J, Kane D, Livingstone W et al. Cytokine gene polymorphisms: Association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003;48:1408-13.
13. Salvarani C, Cantini F, Olivieri I. Disease-modifying antirheumatic drugs therapy for psoriatic arthritis. Clin Exp Rheumatol 2002;20(Suppl 28):S71-5.
14. Salvarani C, Olivieri I, Cantini F, Macchioni P, Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998;10:299-305.
15. Gladman DD. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 2003;33:29-37.
16. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64:iI74-7.
17. Kaltwasser JP, Nash P, Gladman DD et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
18. Mease PJ, Antoni CE. Psoriatic arthritis treatment: Biological response modifiers. Ann Rheum Dis 2005;64:78-82.
19. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. J Rheumatol 2006;33:1422-30.
20. Gladman DD, Tung Hing ENG, Schentag CT, Cook RJ. Remission in psoriatic arthritis. J Rheumatol 2001;28:1045-8.
21. Pinals RS, Masi AT, Larsen RA. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
22. Harrison BJ, Symmons DP, Brennan P, Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: Issues of definition and prediction. Br J Rheumatol 1996;35:1096-100.
23. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
25. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
26. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.
27. Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-4.
28. Cantini F, Salvarani C, Olivieri I et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia reumatica: A prospective follow-up study. Semin Arthritis Rheum 2000;30:17-24.
29. Sheldon J. Laboratory testing in autoimmune diseases. Best Pract Res Clin Rheumatol 2004;18:249-69.
30. Gladman DD, Stafford-Brady F, Chang CH, Lewandosky K, Russel ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
31. Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthitis: A systematic analysis of 127 cases. Am J Med 1973;55:445-52.
32. Jones G, Crotty M, Brooks P. Psoriatic arthritis: A quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. Br J Rheumatol 1997;36:95-9.
33. Mease PJ, Antoni CE. Psoriatic arthritis treatment: Biological response modifiers. Ann Rheum Dis 2005;64(Suppl II):iI78-82.
34. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. J Rheumatol 1985; 12:245-52.
35. Prevoo MLL, van Gestel AM, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatology Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
36. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003;30:1138-46.
37. Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tina X, Sanmarti R. Value of DAS 28 and DAS 28-3 as compared to ACR-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-6.
38. de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: A 26-week observational study. Rheumatology 2006;45:321-4.
39. Salvarani C, Cantini F, Olivieri I et al. Isolated peripheral enthesitis and/or dactylitis: A subset of psoriatic arthritis. J Rheumatol 1997;24:1106-10.